^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lucentis (ranibizumab)

    i
    Associations
    News

    Trials

    Company:
    Novartis, Roche
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (NCT03161652)
    Phase 2
    Carmen Clapp
    Recruiting
    Last update posted :
    08/25/2023
    Initiation :
    05/24/2017
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    PRL
    |
    Lucentis (ranibizumab)
    A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (NCT02859441)
    Phase 1/2
    National Eye Institute (NEI)
    Completed
    Last update posted :
    11/01/2021
    Initiation :
    01/23/2017
    Primary completion :
    07/09/2019
    Completion :
    07/09/2019
    VHL
    |
    VHL mutation
    |
    Fovista (pegpleranib) • Lucentis (ranibizumab)
    Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 (NCT00657202)
    Phase 1
    Massachusetts General Hospital
    Completed
    Last update posted :
    07/07/2016
    Initiation :
    03/01/2008
    Primary completion :
    10/01/2009
    Completion :
    12/01/2013
    NF1
    |
    Lucentis (ranibizumab)